LG Chem
As of the edition of 20 October 2026, LG Chem runs 17 drugs, 3 of them marketed; it is on route A at 2 targets and on route B at 5 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
- AVEO Pharmaceuticals, Inc.: acquired
Drugs by status
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 5 |
| Went quiet | 4 |
| Status not established | 5 |
| Total | 17 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Somatropin | Ended 2003 (orphan exclusivity) | 4 |
| Tivozanib | Ends 2028 (patent) | 5 |
| Gemifloxacin | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 2 targets, route B at 5 targets.
All 7 rows on route A or B
In the product7 company-target rows on route A or B; 4 are not shown here, and no score is.
See all 7 targets where LG Chem needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 23 trials led
- Nutrition and metabolism: 14 trials led
- Bones, joints and muscles: 9 trials led